Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Stemnovate Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being examined by 1 distinct examiner, Andrea Steffel Olson, in 1 distinct art unit. Andrea Steffel Olson is the busiest examiner, with 1 pending office action. The portfolio's current activity is limited to this single examiner and art unit. This concentration suggests a focused prosecution strategy for the company's pending biotechnology matters.
The involvement of 1 distinct examiner and 1 distinct art unit means that the 1 pending office action is subject to a single set of examination criteria. Because Andrea Steffel Olson is the only examiner currently active for the company, her individual approach will define the immediate results. This centralized structure in the Biotechnology & Pharmaceuticals sector provides a clear and predictable path for the company's intellectual property. Practitioners can efficiently manage this portfolio by focusing on the specific standards and history of the 1 distinct examiner involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17703152 | METHOD | OLSON, ANDREA STEFFEL | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17703152 | METHOD | OLSON, ANDREA STEFFEL | 1656 | §102§103§112 | Non-Final OA | — | Pending | Mar 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStemnovate Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrea Steffel Olson has the most, with 1 of Stemnovate Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
